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a web-based Delphi study
GuNhIlD NybOrG, JøruND StraaND, atle KlOvNING & Mette breKKe
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abstract
Objective. to develop a set of explicit criteria for pharmacologically inappropriate medication use in nursing homes. 
Design. In an expert panel, a three-round Delphi consensus process was conducted via survey software. Setting. Norway. 
Subjects. altogether 80 participants – specialists in geriatrics or clinical pharmacology, physicians in nursing homes and 
experienced pharmacists – agreed to participate in the survey. Of these, 62 completed the first round, and 49 panellists 
completed all three rounds (75.4% of those ultimately entering the survey). Main outcome measures. the authors developed 
a list of 27 criteria based on the Norwegian General Practice (NOrGeP) criteria, literature, and clinical experience. 
the main outcome measure was the panellists’ evaluation of the clinical relevance of each suggested criterion on a digital 
likert scale from 1 (no clinical relevance) to 10. In the first round panellists could also suggest new criteria to be included 
in the process. For each criterion, degree of consensus was based on the average likert score and corresponding standard 
deviation (SD). Results. a list of 34 explicit criteria for potentially inappropriate medication use in nursing homes was 
developed through a three-round web-based Delphi consensus process. Degree of consensus increased with each round. 
No criterion was voted out. Suggestions from the panel led to the inclusion of seven additional criteria in round two. 
Implications. the NOrGeP-Nh list may serve as a tool in the prescribing process and in medication list reviews and may 
also be used in quality assessment and for research purposes.
Key Words:  Delphi technique, explicit criteria, general practice, inappropriate medication use, Norway, nursing homes, 
pharmacoepidemiology
[4]. Still there is often limited research evidence of 
effects and side effects, because most randomized, 
controlled trials on drug treatment are conducted in 
younger populations where comorbidities and polyp-
harmacy are common exclusion criteria.
various lists of explicit criteria for pharmacolog-
ical inappropriateness have been developed to guide 
clinical practice and for assessing the extent of poten-
tially inappropriate medication (PIM) use in the 
elderly [5,6]. the beers criteria were developed in 
the uS in 1991 for Nh residents [7] and later for a 
general population [8–10]. In europe the StOPP-
Start criteria, designed for a general elderly 
population, were published in 2008 [11] and the 
German PrISCuS list was developed in 2010 [12]. 
introduction
the nursing home (Nh) population of Western 
countries has become increasingly frail and ill, with 
specific and extensive needs in terms of health care. 
a recent uK survey found that 56% of the residents 
in 38 Nhs died within a year of admission [1]. In 
Norway, only 29% of long-term residencies in Nhs 
exceeded two years’ length in 2012 [2]. the majority 
of patients have multiple diseases with an average of 
four active diagnoses, four out of five residents have 
extensive needs for assistance in carrying out activi-
ties of daily living [2], and four out of five have 
dementia [3].
In general, the elderly population is more prone 
to medication side effects and drug–drug interactions 
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 Prescription criteria for nursing homes  135
the Norwegian General Practice (NOrGeP) crite-
ria are another list of explicit criteria for pharmaco-
logical inappropriateness, targeting home-dwelling 
elderly seen in general practice [13]. the NOrGeP 
list consists of 36 statements including 21 single 
drugs and 15 drug–drug combinations. the list is 
partly based on the beers’ criteria and it was derived 
through a three-round Delphi consensus process car-
ried out in 2006 by a large expert panel consisting 
of geriatricians, GP specialists, and clinical pharma-
cologists. according to the NOrGeP criteria, one-
third of the total population of home-dwelling elderly 
in Norway was exposed to at least one PIM over 
the course of one year in 2008 [14]. a study from 
Norwegian Nhs based on 28 of the 36 NOrGeP 
criteria revealed a prevalence of PIM of 31% [15].
Some studies have shown an impact of inappro-
priate drug regimens on health care outcomes like 
hospital admission rates [16,17], self-perceived health 
status [18], and health-care utilization [19], while 
others have found no association between PIMs and 
the length of hospital stay [18]. two studies found 
no association between PIMs and mortality [16,20]. 
In one study, inappropriate medication use increased 
the risk of adverse drug events when measured by 
the StOPP criteria; however, when applying the 
beers criteria the correlation was not significant [21]. 
there is a need for more evidence as to the clinical 
relevance of the different lists of explicit criteria when 
it comes to effect on patient-related health outcomes. 
In the present study we aimed at establishing an 
updated and clinically relevant tool for assessing 
medication use in Nh residents.
Material and methods
We conducted a three-round consensus process using 
the Delphi technique [22]. the Delphi technique is a 
structured communication technique where a panel 
of experts answers questions, most often in the form 
of a questionnaire, to which there are no scientifically 
proven correct answers [22]. the idea is that a group 
of experts, participating individually and anonymously, 
will give a more valid approach than experts one by 
one, and that consensus is reached through consecu-
tive rounds in which participants are shown average 
responses made by the panel in previous rounds.
In august 2011 we invited by e-mail all members 
of the Norwegian Geriatrics Society (NGS, n  122) 
and the Norwegian Society of Clinical Pharmacology 
(NFKF, n  48) to participate. We also invited five 
pharmacists known to have particular expertise in 
medication safety, a convenience sample of Nh 
physicians working in Oslo (n  55), and all members 
of the Norwegian College of General Practitioners’ 
reference Group for Nh medicine (n  11). alto-
gether, the number of eligible doctors in the five groups 
was 241. a total of 92 doctors responded to the invita-
tion, and 80 agreed to participate (Figure 1).
the three rounds of the Delphi process were 
completed between august 2011 and March 2012. 
the survey was conducted via the software Survey-
Monkey® (Madison, WI, uS), and the participants 
were sent an e-mail with a link to the survey. In first 
round they were exposed to 27 statements, suggest-
ing criteria for inappropriate medication use in Nh 
residents. the proposed criteria were based on the 
NOrGeP criteria [13] and the knowledge and expe-
rience of the authors, who also carried out a com-
prehensive literature search for each suggested 
criterion. a few of the criteria from the NOrGeP 
list have since their publication been taken off market 
and a few of them were shown to be of little clinical 
relevance in a subsequent pharmacoepidemiological 
national study [14] and these criteria were not 
included here. Other criteria given as single drug cri-
teria in the NOrGeP were here listed as drug classes 
(first-generation tricyclic antidepressants [tCas], 
first-generation antihistamines, and neuroleptics). 
each statement was presented with a brief explana-
tion and up to three literature references. a com-
mentary box was provided beneath each criterion. In 
addition, the participants were encouraged to suggest 
additional criteria and references.
a new literature search was performed before the 
authors decided whether or not to include criteria 
proposed by the panellists in the first round. the 
revised list of criteria was presented to the panellists 
in round two, in which average relevance scores from 
the first round were included. In the second round 
there was still room for comments but not for 
suggesting additional criteria. In the third round 
average scores for each criterion in round two were 
enclosed and the panellists were asked only to score 
without comments. a link for opting out was 
provided in each mail.
Main outcome was the panellists’ evaluation of the 
clinical relevance in an Nh setting of each statement 
Nursing home residents are frail and thus are 
especially prone to medication side effects and 
drug interactions.
this paper describes a three-round Delphi  •
process, resulting in a list of drugs, dosages, 
and drug combinations to be avoided in 
nursing home residents for safety reasons.
the list may serve as a tool in the prescribing  •
process and in medication reviews.
the list may also be used in quality assessment  •
and for research purposes.
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136 G. Nyborg et al. 
as scored on a digital likert scale from 1 (no clinical 
relevance) to 10 (highly clinically relevant) [23,24].
Statistics
For each criterion, degree of consensus was based on 
the average likert score and corresponding standard 
deviation (SD). SDs described the degree of discor-
dance through the three rounds. Statements were 
included in the final list if the mean score minus one 
SD exceeded 5 in round three.
Subgroup analyses were performed comparing 
scores made by the Nh physician group with cor-
responding scores made by the rest of the panel. 
because frequency distributions were skewed towards 
the right and thus were not normally distributed, 
Mann–Whitney u-tests were employed to analyse 
differences in consensus between the two groups. 
the participants were assumed independent of each 
other, since the survey was conducted via Internet 
and not in a face-to-face group. because of the large 
number of statistical tests significance was set to 
p  0.01. analyses were performed using IbM SPSS 
Statistics version 20.
Ethics
the study protocol was presented to and approved 
by the Norwegian Social Sciences Data Services 
(NSD). Since there was no intervention as such and 
all correspondence and comments were anonymous 
the NSD assessed that the study did not need explicit 
approval by the regional Committee for Medical 
and health research ethics.
results
We received altogether 92 responses from 34 Oslo 
nursing home physicians, nine members of the refer-
ence Group for Nh medicine (some of whom also 
were physicians in Oslo nursing homes), 13 members 
of NFKF, 38 members of NGF, and all five pharma-
cists. Of these, 80 participants agreed to take part in 
the survey out of which 52 completed all three rounds 
and 49 provided complete data (see Figure 1). the 
first round comprised 27 statements to be scored 
while the second and third rounds held a total of 34 
statements, seven of which were based on the panel-
lists’ suggestions in the first round. Five participants 
Figure 1. the Delphi process, setting, and participants. 1Nursing home physicians (n  55), members of the Clinical reference Group for 
Nursing homes (n  11), geriatricians (n  122), clinical pharmacologists (n  48), pharmacists (n  5). two of the doctors in the CrGNh 
were also nursing home physicians in Oslo and are represented in both groups here.
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 Prescription criteria for nursing homes  137
gave reasons for not completing the survey; the rest 
opted out by not responding to it. Of the 49 partici-
pants completing all three rounds, 15 (30.6%) were 
specialists in geriatrics, five (10.2%) specialists in 
clinical pharmacology, and five (10.2%) pharmacists, 
thus making up a group of 25. the other 24 (49.0%) 
respondents were Nh physicians, some members of 
the General Practitioners’ reference Group for 
Nh medicine.
all proposed criteria were included in the final list 
(table I). there was generally a high score for clinical 
relevance for most criteria, 26 of them receiving a 
mean score  8.0 for the first round the criterion was 
included (table II). For all criteria the relevance 
table I. Norwegian General Practice Nursing home (NOrGeP-Nh) criteria for potentially inappropriate medication use 
in elderly ( 70 years) nursing home residents.
a: Single substance criteria Comments, adverse effects
Regular use should be avoided
 1. Combination analgesic codeine/paracetamol Poor long-term effects. Constipation, sedation, falls
 2. tricyclic antidepressants (tCas)1 anticholinergic effects, cardiotoxicity
 3. Non-steroid anti-inflammatory drugs (NSaIDs) high risk of side effects and interactions
 4. First-generation antihistamines2 anticholinergic effects, prolonged sedation
 5. Diazepam Over-sedation, falls, fractures
 6. Oxazepam: Dosage  30 mg/day Over-sedation, falls, fractures
 7. Zopiklone: Dosage  5 mg/day Over-sedation
 8. Nitrazepam Over-sedation, falls, fractures
 9. Flunitrazepam Over-sedation, falls, fractures, addiction
10. Chlometiazole Poor safety record. risk of cardiopulmonary death
11. regular use of hypnotics Over-sedation, falls, fractures
b: Combination criteria
Combinations to avoid
12. Warfarin  NSaIDs Increased risk of bleeding
13. Warfarin  SSrIs/SNrIs3 Increased risk of bleeding
14. Warfarin  ciprofloxacin/ofloxacin/erythromycin/
clarithromycin
Increased risk of bleeding
15. NSaIDs/coxibs4  aCe-inhibitors5/at2-antagonists6 Increased risk of kidney failure
16. NSaIDs/coxibs  diuretics reduced effect of diuretics, risk of heart and kidney failure
17. NSaIDs/coxibs  glucocorticoids Increased risk of bleeding, fluid retention
18. NSaIDs/coxibs  SSrI/SNrIs Increased risk of bleeding
19. aCe-inhibitors/at2-antagonists  potassium or 
potassium-sparing diuretics
Increased risk of hyperkalaemia
20. beta blocking agents  cardioselective calcium 
antagonists
Increased risk of atrioventricular block, myocardial depression, 
hypotension, orthostatism
21. erythromycin/clarithromycin  statins Increased risk of adverse effects of statins
22. bisphosphonate  proton pump inhibitors Increased risk of fractures
23. Concomitant use of 3 or more psychotropics7 Increased risk of falls, impaired memory
24. tramadol  SSrIs risk of serotonin syndrome
25. Metoprolol  paroxetine/fluoxetine/bupropion hypotension, orthostatism
26. Metformin  aCe-inhibitor at2-antagonists  
diuretics
risk of impaired renal function and metformin-induced 
lactacidosis, especially in dehydration
C: Deprescribing criteria. Need for continued use should be 
reassessed8
27. anti-psychotics (incl. “atypical” substances9) Frequent, serious side effects. avoid long-term use for bPSD10
28. anti-depressants limited effect on depression in dementia
29. urologic spasmolytics limited effect for urinary incontinence in old age risk of 
anticholinergic side effects
30. anticholinesterase inhibitors temporary symptomatic benefits only. Frequent side effects
31. Drugs lowering blood pressure hypotension, orthostatism, falls
32. bisphosphonates assess risk–benefit in relation to life expectancy
33. Statins assess risk–benefit in relation to life expectancy
34. any preventive medicine assess risk–benefit in relation to life expectancy
 Notes: 1amitriptyline, doxepine, chlomipramine, trimipramine, nortryptiline; 2dexchlorfeniramine, promethazine, hydroxyzine, alimemazine 
(trimeprazine); 3selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors; 4cyclooxygenase-2-selective inhibitors; 
5angiotensin-converting enzyme inhibitors; 6angiotensin II receptor antagonists; 7from the groups centrally acting analgesics, antipsychotics, 
antidepressants, and/or benzodiazepines; 8this should be undertaken at regular intervals. For criteria 27–29, a safe strategy for re-evaluation 
is first to taper dosage, then stop the drug while monitoring clinical condition; 9risperidone, olanzapine, quetiapine, aripiprazole; 10behavioural 
and psychological symptoms in dementia.
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138 G. Nyborg et al. 
scores increased through the second and third rounds: 
28 of the 34 criteria attained a final average score  9 
in round three. For all criteria the SD was reduced 
from first to third round, reflecting fewer outliers at 
the lower end of the scale. three criteria with an aver-
age score  8 in the first round had a final score  9 
in the third round, namely non-steroidal anti-inflam-
matory drugs (NSaIDs) in general, anti-psychotics 
in absence of psychosis, and first generation of anti-
histamines. Only the criterion regarding concurrent 
use of proton pump inhibitors (PPIs) and bisphos-
phonates still had a score  8 in round three.
through all three rounds 27 criteria were assessed 
three times by the panel while seven were scored 
twice, resulting in 95 means altogether (see table II). 
When comparing mean scores made by Nh physi-
cians with those made by the group of geriatricians, 
clinical pharmacologists, and pharmacists (Mann– 
Whitney u-test with p  0.01 to correct for the large 
number of tests) we only found a significant but small 
table II. Norwegian General Practice Nursing home (NOrGeP-Nh) criteria for potentially inappropriate medication use 
in nursing home residents.1 Mean scores with standard deviations and final score.
Criterion:
round 1 
MS (SD)
round 2  
MS (SD)
round 3  
MS (SD)
Final  
score2
a: Single substance criteria. the following should be avoided for 
regular use whenever possible:
 1. Combination analgesic with codeine/paracetamol 6.5 (2.3) 8.3 (1.8) 8.5 (1.4) 7.1
 2. tricyclic antidepressants (tCas) for depression 7.2 (2.1) 9.1 (1.2) 9.5 (0.7) 8.8
 3. NSaIDs 8.8 (2.0) 9.8 (0.6) 9.8 (0.5) 9.3
 4. First-generation antihistamines 7.6 (2.4) 8.6 (1.6) 9.3 (1.0) 8.3
 5. Diazepam 9.1 (1.7) 9.6 (1.0) 9.7 (1.0) 8.7
 6. Oxazepam: Dosage  30 mg/day 8.8 (1.5) 9.4 (1.2) 9.6 (1.0) 8.6
 7. Zopiklone: Dosage  5 mg/day 7.6 (2.4) 8.1 (2.0) 8.5 (1.8) 6.7
 8. Nitrazepam 8.7 (1.9) 9.5 (1.0) 9.7 (0.8) 9.1
 9. Flunitrazepam 9.3 (1.5) 9.8 (0.6) 9.9 (0.2) 9.7
10. Chlometiazole 8.6 (1.9) 9.1 (1.2) 9.2 (1.3) 7.9
11. regular use of hypnotics N/a3 8.5 (2.0) 9.2 (1.3) 7.9
b: Combination criteria. the following drug combinations  
should be avoided whenever possible:
12. Warfarin  NSaIDs 9.6 (1.1) 10.0 (0.1) 10.0 (0.3) 9.7
13. Warfarin  SSrI/SNrI 7.3 (2.5) 7.8 (1.5) 8.1 (1.4) 6.7
14. Warfarin  ciprofloxacin/ofloxacin/ erythromycin/ 
clarithromycin
8.1 (2.4) 9.1 (1.3) 9.2 (1.1) 8.1
15. NSaIDs/coxibs  aCe-inhibitors/at2-antagonists 9.1 (1.3) 9.4 (1.1) 9.6 (1.0) 8.6
16. NSaIDs/coxibs  diuretics 8.0 (2.2) 8.6 (1.8) 9.2 (1.6) 7.6
17. NSaIDs/coxibs  glucocorticoids 8.2 (2.1) 9.2 (1.3) 9.5 (0.9) 8.6
18. NSaIDs/coxibs  SSrI/SNrIs 7.2 (2.5) 8.1 (1.9) 8.8 (1.5) 7.3
19.  aCe-inhibitors/at2-antagonists  potassium or potassium-
sparing diuretics
8.4 (2.0) 9.2 (1.3) 9.6 (0.8) 8.8
20. beta blocking agents  cardioselective calcium antagonists 8.5 (2.0) 9.3 (1.2) 9.6 (0.8) 8.8
21. erythromycin/clarithromycin  statins 8.3 (2.0) 9.5 (0.9) 9.6 (0.8) 8.8
22. bisphosphonate  proton pump inhibitors 6.6 (2.4) 6.8 (2.1) 7.4 (1.8) 5.6
23. Concomitant use of three or more psychotropic drugs 9.6 (0.7) 9.9 (0.5) 10.0 (0.1) 9.9
24. tramadol  SSrIs N/a2 8.5 (1.8) 9.2 (0.9) 8.3
25. Metoprolol  paroxetine/fluoxetine/bupropion N/a2 8.9 (1.1) 9.1 (1.0) 8.1
26. Metformin  aCe-inhibitors/at2-antagonists  diuretics N/a2 8.4 (1.8) 8.6 (1.4) 7.2
C: De-prescribing criteria. Need for continued use should be 
reassessed4
27. anti-psychotics 7.6 (1.9) 9.5 (1.4) 9.7 (0.8) 8.9
28. anti-depressants 8.6 (0.9) 9.9 (0.2) 10.0 (0.0) 10.0
29. urologic spasmolytics 8.9 (1.6) 9.7 (0.7) 9.9 (0.4) 9.5
30. anticholinesterase inhibitors 9.4 (1.1) 9.8 (0.4) 9.9 (0.7) 9.2
31. Drugs that lower blood pressure N/a2 9.9 (0.5) 10.0 (0.2) 9.8
32. bisphosphonates N/a2 9.7 (0.9) 9.9 (0.4) 9.5
33. Statins 9.1 (1.3) 9.7 (0.9) 9.9 (0.5) 9.4
34. General use of preventive medication N/a2 9.6 (1.0) 9.9 (0.4) 9.5
 Notes: 1the clinical relevance for each of the criteria is scored (from 1 to 10) by a panel of experts during a three-round consensus process. 
Figures are mean scores with standard deviation, MS (SD). 2Final score (column to the right) is mean score in round 3 minus 1 SD in 
round 3. to be included on final NOrGeP-Nh list, final score should be  5. 3Not available, this denotes criteria first entered into the 
Delphi process in round 2. 4More details are given in table I.
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difference for five out of 95 mean scores. For one 
criterion there was a difference in round 1 (p  0.002) 
and 3 (p  0.004), but not round 2 (p  0.06), namely 
the combination of NSaIDs with selective serotonin 
reuptake inhibitors/selective norepinephrine reuptake 
inhibitors (SSrIs/SNrIs), where the nursing home 
physicians scored higher compared with the other 
group. the nursing home physicians were also more 
restrictive regarding NSaIDs in general (p  0.001), 
statins (p  0.001), and the combination of systemic 
NSaIDs/coxibs  systemic glucocorticoids (p  0.008) 
in round 1 than the other group, but in later rounds 
no such difference was found.
Discussion
this three-round Delphi process, carried out among 
80 participants, resulted in a list of 34 criteria for 
potentially inappropriate medication use in Nhs. 
both the degree of consensus and the average scores 
for clinical relevance increased throughout the Delphi 
process. a corresponding trend was also seen in the 
NOrGeP Delphi process [13]. a Delphi technique 
is said to be useful when a problem does not lend 
itself to precise analytical techniques, but can benefit 
from subjective judgements on a collective basis [22]. 
however, the initial 27 suggestions, and the seven 
criteria suggested by the panel, are all based on a 
combination of experience among both the authors 
and the panel and evidence from the literature. all 
suggestions have been scrutinized through literature 
searches and relevant references were provided to the 
panel during the consensus process.
the standard deviations of the means can be 
interpreted as a measure of the degree of discord 
among the participants. however, our data did not 
follow a normal distribution, as most participants’ 
scores were in the high range (right skewed distribu-
tion), especially in round 3, thus the SD will be 
inflated and not give an exact measure of the variance 
[25]. Still, a larger SD implies that a larger number 
of participants scored well below the mean. the Del-
phi technique in itself can be said to be conservative 
in the respect that it takes quite a lot for a proposed 
criterion to be rejected. the main reasons for the 
Delphi method to fail are imposing monitor views 
and preconceptions upon the respondent group, and 
ignoring and not exploring disagreements [22]. In 
order to avoid falling into these traps and including 
criteria for which there was substantial discord, we 
decided that a criterion be included in the final list 
only if (mean –1SD)  5, so that not only was the 
mean score taken into consideration but also the 
degree of discord. In a case with a high degree of 
disagreement, as seen by a high SD, the average 
minus SD will thus be lower than in a case with a 
high general agreement (and thus a low SD). In this 
way, a controversial criterion will be less likely to be 
included in the list than a less controversial. Still no 
criterion was voted out through the three rounds.
Out of the 80 doctors who initially agreed to take 
part in the survey, 49 (61%) completed all three 
rounds. Of these 24 (49%) were nursing home phy-
sicians. the survey was lengthy, with a lot of text and 
many references, and this might have added to the 
withdrawal percentage. however, participants who 
completed all three rounds were in large part active 
throughout the process, providing numerous com-
ments and suggestions for further references in both 
rounds one and two, thus giving the impression of 
an involved and independent panel.
It has been argued that one of the most critical 
aspects when designing a Delphi survey is the selec-
tion of qualified experts [22]. In some earlier surveys, 
among them the beers consensus process and its 
later updates [7,8,10], the recruitment process dif-
fered from the present study in that the panel con-
sisted of considerably fewer, hand-picked experts: 12 
and six in the case of beers criteria for Nhs. the 
Delphi process leading to the NOrGeP criteria, 
however, included a panel of 47 doctors [13]. at 
present there is no vocational training leading to a 
clinical speciality within Nh medicine in Norway. 
thus we do not know Nh doctors’ level of expertise 
and experience. to check for robustness with regard 
to this matter we tested the average scores and the 
development of consensus throughout the survey’s 
three rounds for these participants versus the rest of 
the panel. using the Mann–Whitney u-test with 
p  0.01 to correct for the large number of tests, we 
found only minor differences between the two groups 
of panellists. the final list of explicit criteria would 
have been unaltered had only either one of the two 
participant groups undertaken the survey.
the final 34 criteria can roughly be divided into 
three groups: single-substance criteria, drug–drug 
combination criteria, and criteria where regular con-
sideration of “de-prescribing” is of uttermost impor-
tance in this population. the term “de-prescribing” 
can be defined as cessation of long-term therapy, 
supervised by a clinician [26]. It has been suggested 
that the term should be adopted internationally by 
researchers and practitioners engaged in this area [27]. 
three criteria in this latter group concern preventive 
drug use when expected remaining life span is short: 
one concerning the use of preventive medication in 
general, the other two concerning the use of, respec-
tively, bisphosphonates and statins. One can argue that 
the two latter criteria are redundant. however, since 
there was consensus to include all three criteria 
throughout the survey, they were included in the final 
list. a similar argument applies to using NSaIDs in 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ite
tbi
bli
ote
ke
t I
 T
ro
nd
he
im
 N
TN
U]
 at
 02
:11
 17
 N
ov
em
be
r 2
01
7 
140 G. Nyborg et al. 
different combinations, all of which could have been 
substituted by a single general criterion. however, 
since some of the combinations are particularly risky, 
the combination criteria still may serve a purpose in 
attracting attention to these potential threats.
the criterion concerning the combination of 
PPIs and bisphosphonates, suggested by one of the 
participants, was the only criterion with a mean 
score  8 in the final round. because this represented 
relatively new knowledge at the time of the survey, 
the lower score can be viewed as healthy scepticism, 
as one could argue that more research was needed. 
after this study was completed, new research has 
strengthened the evidence for the clinical relevance 
of avoiding this combination, which is associated 
with increased risk for fractures [28,29].
the criteria concerning concomitant use of SSrI/
SNrI, and warfarin and NSaIDs respectively, do not 
distinguish between different SSrI/SNrI. however, 
different SSrI/SNrI represent a varying increase in 
the risk of bleeding when combined with anticoagu-
lants due to differences in serotonin inhibition [30].
the Norwegian General Practice Nursing home 
(NOrGeP-Nh) criteria resulting from this survey 
can be used as a reminder for Nh physicians in their 
daily clinical work, and may also be useful for phar-
macoepidemiological research and quality assess-
ment work. In a previous study we found that 
one-third of the total population of home-dwelling 
elderly in Norway were exposed to at least one PIM 
over the course of one year, according to a modified 
version of the NOrGeP criteria [14]. the present 
list, although primarily developed for the especially 
frail patients in nursing homes, can also be useful as 
a tool for GPs undertaking medication reviews for 
elderly patients outside institutions.
there is a need for more research on the effects 
of implementing the NOrGeP-Nh and similar lists 
with explicit criteria in clinical practice on outcomes 
like quality of life, morbidity, and mortality. 
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